Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$51.17 - $68.18 $5.28 Million - $7.03 Million
-103,100 Reduced 54.69%
85,400 $4.61 Million
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $10.2 Million - $14.9 Million
167,300 Added 789.15%
188,500 $12.8 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $818,744 - $1.53 Million
21,200 New
21,200 $1.33 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $5.5 Million - $8.57 Million
-126,500 Reduced 84.11%
23,900 $1.34 Million
Q1 2023

May 15, 2023

BUY
$41.0 - $56.12 $2.98 Million - $4.07 Million
72,600 Added 93.32%
150,400 $6.8 Million
Q4 2022

Feb 13, 2023

BUY
$39.19 - $65.67 $1.2 Million - $2 Million
30,500 Added 64.48%
77,800 $3.16 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $1.07 Million - $1.47 Million
17,500 Added 58.72%
47,300 $3.09 Billion
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $1.16 Million - $1.98 Million
-26,800 Reduced 47.35%
29,800 $1.81 Million
Q1 2022

May 12, 2022

BUY
$53.19 - $79.24 $1.81 Million - $2.7 Million
34,100 Added 151.56%
56,600 $3.55 Million
Q4 2021

Feb 10, 2022

SELL
$70.09 - $111.29 $4.44 Million - $7.04 Million
-63,300 Reduced 73.78%
22,500 $1.71 Million
Q1 2021

May 14, 2021

BUY
$110.72 - $210.04 $7.67 Million - $14.6 Million
69,300 Added 420.0%
85,800 $10.5 Million
Q2 2020

Aug 13, 2020

SELL
$38.5 - $76.05 $42,350 - $83,655
-1,100 Reduced 6.25%
16,500 $1.21 Million
Q1 2020

May 13, 2020

BUY
$33.68 - $62.53 $16,840 - $31,265
500 Added 2.92%
17,600 $746,000
Q4 2018

Feb 13, 2019

SELL
$22.73 - $42.34 $738,725 - $1.38 Million
-32,500 Reduced 65.52%
17,100 $489,000
Q3 2018

Nov 14, 2018

BUY
$44.35 - $65.71 $2.2 Million - $3.26 Million
49,600 New
49,600 $2.2 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.05B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.